帕罗西汀治疗高血压合并抑郁焦虑障碍患者的疗效观察  

Efficacy observation of Paroxetine in in patients with hypertension complicated with depression and anxiety disorders

作　　者：郭亮[1] 杨红梅[1] 梁家騋[1] 孙克峰[1] 杨猛[1] 

机构地区：[1]济南市精神卫生中心,山东济南250032

出　　处：《中国民康医学》2017年第3期7-8,20,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察帕罗西汀治疗高血压合并抑郁焦虑障碍患者的疗效和安全性。方法:将60例抑郁焦虑障碍患者分为研究组和对照组,每组各30例。研究组患者为高血压合并抑郁焦虑障碍;对照组患者为同期无高血压的抑郁焦虑障碍。两组患者均采用帕罗西汀治疗共8周,采用HAMD、HAMA及TESS评定两组患者的疗效和不良反应。结果:治疗后,两组患者的收缩压和舒张压均较治疗前下降,但无统计学意义(P>0.05)。两组患者的HAMD和HAMA评分,与治疗前比较均有显著性下降(P<0.01);两组患者显效率无明显差异(P>0.05);两组患者的不良反应发生率无明显差异(P>0.05)。结论:帕罗西汀治疗高血压合并抑郁焦虑障碍患者的疗效好,安全性高。Objective To observe efficacy and safety of Paroxetine in treatment of in patients with hypertension complicatedwith depression and anxiety disorders. Methods ： 30 patients with hypertension complicated with depression and anxiety disorders were selected as research group, while other 30 patients with depression and anxiety disorders but without hypertension were used as control group. The two groups were treated with Paroxetine for 8 weeks. Hamilton depression scale （ HAMD） , Hamilton anxiety scale （ HA-MA） ,and treatment emergent symptom scale （TESS） were applied to evaluate the curative effects and adverse reactions. Results ： The systolic pressure and diastolic blood pressure after the treatment in research group and control group decreased compared with those before the treatment,but the differences were not statistically significant （ P〉0. 05）. The two groups＇ HAMA and HAMD scores after the treatment were significantly reduced compared with those before the treatment,and the differences were statistically significant （ P〈 0.01）. There was no significant difference in the obvious effective rate between the two groups （ P〉0.05）. The incidence of adverse reactions of the two groups had no statistical significance （ P〉0.05）. Conclusions ： Paroxetine in the treatment of hypertension compli-cated with depression and anxiety disorders has good effects and high safety.

关 键 词：帕罗西汀 高血压 抑郁症 焦虑障碍 

分 类 号：R749.41[医药卫生—神经病学与精神病学] R544.1[医药卫生—临床医学]